Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
Immune response against medullary thyroid carcinoma (MTC) induced by parental and/or interleukin-2-secreting MTC cells in a rat model of human familial medullary thyroid carcinoma.
Cancer Immunol Immunother. 1996 Oct;43(2):116-23. Unique Identifier : AIDSLINE MED/97112466 Lausson S; Fournes B; Borrel C; Milhaud G; Treilhou-Lahille F; Laboratoire d'Endocrinologie Cellulaire et Evolution, U. R. A.; 1116 CNRS, Universite Paris-Sud, Centre d'Orsay, France.
Abstract:
The existence of inherited aggressive forms of medullary thyroid carcinoma (MTC), and their resistance to all classical therapies, make it a prime candidate for adoptive immunotherapy. As a prelude to a vaccine for the protection of family members at risk of developing the disease, we investigated the immunological antitumour response provoked by the 6/23 rMTC cell line, compared to that of the same cell engineered to secrete interleukin-2 (rMTC-IL2), in an animal model of familial human MTC, the inbred strain of Wag/Rij rats. The rMTC cells developed a tumour that invaded the whole neck 15 days after orthotopic injection (into the thyroid), while the rMTC-IL2 cells were progressively rejected. Co-injection of rMTC-IL2 with the parental cells induced the rejection of the rMTC transplants. When injected, both tumoral cell types showed a similar positive immunoreaction with anti-MHC class I (major histocompatibility complex class I) antibodies. They both recruited natural killer cells and eosinophils at the site of injection. In addition, CD8+ T lymphocytes infiltrated the rMTC-IL2 cells, and eosinophil recruitment was amplified. Neutrophils, macrophages and CD4+ T lymphocytes were scarce. Our results suggest that the CD8+ T lymphocytes are implicated in the anti-tumour reaction elicited by the IL-2-transfected cells. As these effectors are known to induce a specific immunological response, including memory, such a protocol should be tested as a vaccine on the young population genetically at risk of developing a MTC.
Keywords: Animal Carcinoma, Medullary/*IMMUNOLOGY/SECRETION/*THERAPY Cell Division/PHYSIOLOGY CD8-Positive T-Lymphocytes/IMMUNOLOGY Disease Models, Animal Histocompatibility Antigens Class I/BIOSYNTHESIS Human *Immunotherapy, Adoptive Injections, Subcutaneous Interleukin-2/GENETICS/*PHYSIOLOGY/*SECRETION Killer Cells, Natural/IMMUNOLOGY Neoplasm Transplantation Rats Rats, Inbred Strains Support, Non-U.S. Gov't Thyroid Neoplasms/*IMMUNOLOGY/SECRETION/*THERAPY Transfection Tumor Cells, Cultured JOURNAL ARTICLE 970228
M9721905
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
